New approaches in the development of a vaccine for mucosal candidiasis: Progress and challenges

Frontiers in Microbiology

Volumn 3, Issue AUG, 2012, Pages

  Vecchiarelli, Anna ^a   Pericolini, Eva ^a   Gabrielli, Elena ^a   Pietrella, Donatella ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

C. Albicans; Candidiasis; Fungal infections; Mucosal candidiasis; Vaccine

Indexed keywords

EID: 84872025496     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2012.00294     Document Type: Review

References (88)

1. Ashman, R. B., Vijayan, D., and Wells, C. A. (2011). IL-12 and related cytokines: function and regulatory implications in Candida albicans infection. Clin. Dev. Immunol. 2011, 686597.
2. Backhed, F., and Hornef, M. (2003). Toll-like receptor 4-mediated signaling by epithelial surfaces: necessity or threat? Microbes Infect. 5, 951-959.
3. Baquir, B., Lin, L., Ibrahim, A. S., Fu, Y., Avanesian, V., Tu, A., Edwards, J. Jr., and Spellberg, B. (2010). Immunological reactivity of blood from healthy humans to the rAls3p-N vaccine protein. J. Infect. Dis. 201, 473-477.
4. Bar, E., Gladiator, A., Bastidas, S., Roschitzki, B., Acha-Orbea, H., Oxenius, A., and Leibundgut-Landmann, S. (2012). A novel Th cell epitope of Candida albicans mediates protection from fungal infection. J. Immunol. 188, 5636-5643.
5. Bozza, S., Montagnoli, C., Gaziano, R., Rossi, G., Nkwanyuo, G., Bellocchio, S., and Romani, L. (2004). Dendritic cell-based vaccination against opportunistic fungi. Vaccine 22, 857-864.
6. Bromuro, C., Romano, M., Chiani, P., Berti, F., Tontini, M., Proi-etti, D., Mori, E., Torosantucci, A., Costantino, P., Rappuoli, R., and Cassone, A. (2010). Beta-glucan-CRM197 conjugates as candidates antifungal vaccines. Vaccine 28, 2615-2623.
7. Calcedo, R., Ramirez-Garcia, A., Abad, A., Rementeria, A., Ponton, J., and Hernando, E L. (2012). Phosphoglycerate kinase and fructose bisphosphate aldolase of Candida albicans as new antigens recognized by human salivary IgA. Rev. Iberoam. Micol. 29, 172-174.
8. Casadevall, A., Dadachova, E., and Pirofski, L. A. (2004). Passive antibody therapy for infectious diseases. Nat. Rev. Microbiol. 2, 695-703.
9. Casadevall, A., and Pirofski, L. A. (2007). Antibody-mediated protection through cross-reactivity introduces a fungal heresy into immunological dogma. Infect. Immun. 75, 5074-5078.
10. Casadevall, A., and Pirofski, L. A. (2012). Immunoglobulins in defense, patho-genesis, and therapy of fungal diseases. Cell Host Microbe 11, 447-456.
11. Cassone, A. (2007). "Fungal vaccines and vaccination: problems and perspective," in Immunology of Fungal Infections, Chap. 21, eds G. D. Brown and M. G. Netea (Dordrecht: Springer), 465-485.
12. Cassone, A., Bromuro, C., Chiani, P., and Torosantucci, A. (2010). Hyr1 protein and beta-glucan conjugates as anti-Candida vaccines. J. Infect. Dis. 202, 1930.
13. Cassone, A., and Casadevall, A. (2012). Recent progress in vaccines against fungal diseases. Curr. Opin. Microbiol. PMID: 22564747. [Epub ahead of print].
14. Cassone, A., De Bernardis, F., Mon-dello, F., Ceddia, T., and Agatensi, L. (1987). Evidence for acorrelation between proteinase secretion and vulvovaginal candidosis. J. Infect. Dis. 156, 777-783.
15. Cassone, A., De Bernardis, F., and San-toni, G. (2007). Anticandidal immunity and vaginitis: novel opportunities for immune intervention. Infect. Immun. 75, 4675-4686.
16. Cassone, A., and Rappuoli, R. (2010). Universal vaccines: shifting to one for many. MBio 1, e00042-10.
17. Conti, H. R., Shen, F., Nayyar, N., Stocum, E., Sun, J. N., Lindemann, M. J., Ho, A. W., Hai, J. H., Yu, J. J., Jung, J. W., Filler, S. G., Masso-Welch, P., Edgerton, M., and Gaffen, S. L. (2009). Th17cellsandIL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J.Exp.Med. 206,299-311.
18. Cutler, C. W., and Jotwani, R. (2006). Dendritic cells at the oral mucosal interface. J. Dent. Res. 85, 678-689.
19. Cutler, J. E. (2005). Defining criteria for anti-mannan antibodies to protect against candidiasis. Curr. Mol. Med. 5,383-392.
20. Cutler, J. E., Corti, M., Lambert, P., Ferris, M., and Xin, H. (2011). Horizontal transmission of Candida albi-cans and evidence of a vaccine response in mice colonized with the fungus. PLoS ONE 6, e22030. doi:10.1371/journal.pone.0022030
21. Cutler, J. E., Deepe, G. S. Jr., and Klein, B. S. (2007). Advances in combating fungal diseases: vaccines on the threshold. Nat. Rev. Microbiol. 5, 13-28.
22. De Bernardis, F., Agatensi, L., Ross, I. K., Emerson, G. W., Lorenzini, R., Sullivan, P. A., and Cassone, A. (1990). Evidence for a role for secreted aspartate proteinase of Candida albi-cans in vulvovaginal candidiasis. J. Infect. Dis. 161, 1276-1283.
23. De Bernardis, F., Amacker, M., Aran-cia, S., Sandini, S., Gremion, C., Zurbriggen, R., Moser, C., and Cassone,A. (2012). A virosomal vaccine against candidal vaginitis: immuno-genicity, efficacy and safety profile in animal models. Vaccine 30, 4490-4498.
24. De Bernardis, F., Boccanera, M., Adriani, D., Spreghini, E., Santoni, G., and Cassone, A. (1997). Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect. Immun. 65, 3399-3405.
25. De Bernardis, F., Santoni, G., Boccanera, M., Lucciarini, R., Arancia, S., Sandini, S., Amantini, C., and Cassone, A. (2010). Protection against rat vaginal candidiasis by adoptive transfer of vaginal B lymphocytes. FEMS Yeast Res. 10,432-440.
26. de Bernardis, F., Santoni, G., Boccanera, M., Spreghini, E., Adriani, D., Morelli, L., and Cassone, A. (2000). Local anticandidal immune responses in a rat model of vaginal infection by and protection against Candida albicans. Infect. Immun. 68, 3297-3304.
27. Diamond, M. E., Sun, L., Ottaviano, A. J., Joseph, M. J., and Munshi, H. G. (2008). Differential growth factor regulation of N-cadherin expression and motility in normal and malignant oral epithelium.J. Cell. Sci. 121, 2197-2207.
28. Farah, C. S., Elahi, S., Drysdale, K., Pang, G., Gotjamanos, T., Seymour, G. J., Clancy, R. L., and Ashman, R. B. (2002). Primary role for CD4(+) T lymphocytes in recovery from oropharyngeal candidiasis. Infect. Immun. 70, 724-731.
29. Fidel, P. L. Jr. (2004). History and new insights into host defense against vaginal candidiasis. Trends Microbiol. 12, 220-227.
30. Fidel, P. L. Jr. (2006). Candida-host interactions in HIV disease: relationships in oropharyngeal candidiasis. Adv. Dent. Res. 19, 80-84.
31. Fidel, P. L. Jr. (2007). History and update on host defense against vaginal candidiasis. Am. J. Reprod. Immunol. 57, 2-12.
32. Fidel, P. L. Jr., and Cutler, J. E. (2011). Prospects for development of a vaccine to prevent and control vaginal candidiasis. Curr. Infect. Dis. Rep. 13, 102-107.
33. Fidel, P. L. Jr., Luo, W., Steele, C., Chabain, J., Baker, M., and Worm-ley, E Jr. (1999). Analysis of vaginal cell populations during experimental vaginal candidiasis. Infect. Immun. 67,3135-3140.
34. Han, Y., Riesselman, M. H., and Cutler, J. E. (2000). Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody. Infect. Immun. 68, 1649-1654.
35. Hornef, M. W., and Bogdan, C. (2005). The role of epithelial Toll-like receptor expression in host defense and microbial tolerance. J. Endotoxin Res. 11, 124-128.
36. Huang, H., Ostroff, G. R., Lee, C. K., Specht, C. A., and Levitz, S. M. (2010). Robust stimulation of humoral and cellular immune responses following vaccination with antigen-loaded beta-glucan particles. MBio 1, e00164-10.
37. Karwa, R., and Wargo, K. A. (2009). Efungumab: a novel agent in the treatment of invasive candidiasis. Ann. Pharmacother. 43, 1818-1823.
38. Kibbler, C. C., Seaton, S., Barnes, R. A., Gransden, W. R., Holli-man, R. E., Johnson, E. M., Perry, J. D., Sullivan, D. J., and Wilson, J. A. (2003). Management and outcome of bloodstream infections due to Candida species in England and Wales. J. Hosp. Infect. 54, 18-24.
39. Kirkpatrick, C. H. (2001). Chronic mucocutaneous candidiasis. Pediatr. Infect. Dis. J. 20, 197-206.
40. Klis, E M., De Koster, C. G., and Brul, S. (2011). A mass spectrometric view of the fungal wall proteome. Future Microbiol. 6,941-951.
41. Li, L., and Dongari-Bagtzoglou, A. (2009). Epithelial GM-CSF induction by Candida glabrata. J. Dent. Res. 88, 746-751.
42. Li, W., Hu, X., Zhang, X., Ge, Y., Zhao, S., Hu, Y., and Ashman, R. B. (2011). Immunisation with the gly-colytic enzyme enolase confers effective protection against Candida albicans infection in mice. Vaccine 29, 5526-5533.
43. Lim, S. M., Jung, H. S., Kim, M. J., Park, D. W., Kim, W. J., Cheong, H. J., Park, S. C., Lee, K. C., Shin, Y. K., Tan, H. K., Kim, S. L., and Sohn, J. W (2007). Immunogenicity and safety of Vi capsular polysaccharide typhoid vaccine in healthy persons in Korea. J. Microbiol. Biotechnol. 17, 611-615.
44. Lindqvist, M., Nookaew, I., Brinken-berg, I., Samuelson, E., Thorn, K., Nielsen, J., and Harandi, A. M. (2011). Unraveling molecular signatures of immunostimu-latory adjuvants in the female genital tract through systems biology. PLoS ONE 6, e20448. doi:10.1371/journal.pone.0020448
45. Liu, Y., and Filler, S. G. (2011). Candida albicans Als3, a multifunctional adhesin and invasin. Eukaryot. Cell 10,168-173.
46. Lopez-Martinez, R. (2010). Candidosis, a new challenge. Clin. Dermatol. 28, 178-184.
47. Luo, G., Ibrahim, A. S., French, S. W., Edwards, J. E. Jr., and Fu, Y (2011). Active and passive immunization with rHyr 1p-N protects mice against hematogenously disseminated candidiasis. PLoS ONE 6, e25909. doi:10.1371/journal.pone.0025909
48. Matthews, R. C., Rigg, G., Hodgetts, S., Carter, T., Chapman, C., Gregory, C., Illidge, C., and Burnie, J. (2003). Preclinical assessment of the efficacy of mycograb, ahuman recombi-nant antibody against fungal HSP90. Antimicrob. Agents Chemother. 47, 2208-2216.
49. Moyes, D. L., and Naglik, J. R. (2011). Mucosal immunity and Candida albicans infection. Clin. Dev. Immunol. 2011, 346307.
50. Moyes, D. L., Runglall, M., Murciano, C., Shen, C., Nayar, D., Thavaraj, S., Kohli, A., Islam, A., Mora-Montes, H., Challacombe, S. J., and Naglik, J. R. (2010). A bipha-sic innate immune MAPK response discriminates between the yeast and hyphal forms of Candida albicans in epithelial cells. Cell Host Microbe 8, 225-235.
51. Naglik, J. R., Challacombe, S. J., and Hube, B. (2003). Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol. Mol. Biol. Rev. 67, 400-428.
52. Naglik, J. R., and Moyes, D. (2011). Epithelial cell innate response to Candida albicans. Adv. Dent. Res. 23, 50-55.
53. Netea, M. G., Brown, G. D., Kullberg, B. J., and Gow, N. A. (2008). An integrated model of the recognition of Candida albicans by the innate immune system. Nat. Rev. Microbiol. 6, 67-78.
54. Netea, M. G., Gow, N. A., Munro, C. A., Bates, S., Collins, C., Ferwerda, G., Hobson, R. P., Bertram, G., Hughes, H. B., Jansen, T., Jacobs, L., Buur-man, E. T., Gijzen, K., Williams, D. L., Torensma, R., McKinnon, A., Mac-Callum, D. M., Odds, E C., Van Der Meer, J. W., Brown, A. J., and Kullberg, B. J. (2006). Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors.J. Clin. Invest. 116,1642-1650.
55. Perruccio, K., Bozza, S., Montagnoli, C., Bellocchio, S., Aversa, F., Martelli, M., Bistoni, F., Velardi, A., and Romani, L. (2004). Prospects for dendritic cell vaccination against fungal infections in hematopoietic transplantation. Blood Cells Mol. Dis. 33, 248-255.
56. Pfaller, M. A., Jones, R. N., Messer, S. A., Edmond, M. B., and Wenzel, R. P. (1998a). National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifun-gal susceptibility in the SCOPE program. Diagn. Microbiol. Infect. Dis. 31,327-332.
57. Pfaller, M. A., Jones, R. N., Messer, S. A., Edmond, M. B., and Wenzel, R. P. (1998b). National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE program. SCOPE participant group. Surveillance and control of pathogens of epidemiologic. Diagn. Microbiol. Infect. Dis. 30, 121-129.
58. Pietrella, D., Mazzolla, R., Lupo, P., Pitzurra, L., Gomez, M. J., Cher-niak, R., and Vecchiarelli, A. (2002). Mannoprotein from Cryptococcus neoformans promotes T-helper type 1 anticandidal responses in mice. Infect. Immun. 70, 6621-6627.
59. Pietrella, D., Rachini, A., Torosantucci, A., Chiani, P., Brown, A. J., Bistoni, R, Costantino, P., Mosci, P., D'enfert, C., Rappuoli, R., Cassone, A., and Vecchiarelli, A. (2010). A beta-glucan-conjugate vaccine and anti-beta-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique. Vaccine 28, 1717-1725.
60. Pirofski, L. A., and Casadevall, A. (2009). Rethinking T cell immunity in oropharyngeal candidiasis. J. Exp. Med. 206, 269-273.
61. Pirofski, L. A., and Casadevall, A. (2012). Q and A: what is a pathogen? A question that begs the point. BMC Biol. 10,6. doi:10.1186/1741-7007-10-6
62. Polonelli, L., Ciociola, T., Magliani, W., Zanello, P. P., D'adda, T., Galati, S., De Bernardis, F., Arancia, S., Gabrielli, E., Pericolini, E., Vecchiarelli, A., Arruda, D. C., Pinto, M. R., Travassos, L. R., Pertin-hez, T. A., Spisni, A., and Conti, S. (2012). Peptides of the constant region of antibodies display fungi-cidal activity. PLoS ONE 7, e34105. doi:10.1371/journal.pone.0034105
63. Polonelli, L., De Bernardis, F., Conti, S., Boccanera, M., Gerloni, M., Morace, G., Magliani, W., Chezzi, C., and Cassone, A. (1994). Idiotypic intrav-aginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies.J. Immunol. 152,3175-3182.
64. Rahman, D., Mistry, M., Thavaraj, S., Challacombe, S. J., and Naglik, J. R. (2007). Murine model of concurrent oral and vaginal Candida albicans colonization to study epithelial host-pathogen interactions. Microbes Infect. 9, 615-622.
65. Raska, M., Belakova, J., Horynova, M., Krupka, M., Novotny, J., Sebestova, M., and Weigl, E. (2008). Systemic and mucosal immunization with Candida albicans hsp90 elicits hsp90-specific humoral response in vaginal mucosa which is further enhanced during experimental vaginal candidiasis. Med. Mycol. 46, 411-420.
66. Remichkova, M., Danova, S., Tucure-anu, C., Lerescu, L., Salageanu, A., and Dimitrova, P. (2009). Effect of Candida albicans dsDNA in gastrointestinal Candida infection. Mycopathologia 167,333-340.
67. Rhee, S. H., Im, E., Riegler, M., Kokko-tou, E., O'brien, M., and Pothoulakis, C. (2005). Pathophysiological role of Toll-like receptor 5 engagement by bacterial flagellin in colonic inflammation. Proc. Natl. Acad. Sci. U.S.A. 102,13610-13615.
68. Roeder, A., Kirschning, C. J., Rupec, R. A., Schaller, M., and Korting, H. C. (2004a). Toll-like receptors and innate antifungal responses. Trends Microbiol. 12, 44-49.
69. Roeder, A., Kirschning, C. J., Rupec, R. A., Schaller, M., Weindl, G., and Korting, H. C. (2004b). Toll-like receptors as key mediators in innate antifungal immunity. Med. Mycol. 42,485-498.
70. Roy, R. M., and Klein, B. S. (2012). Dendritic cells in antifungal immunity and vaccine design. Cell Host Microbe 11,436-446.
71. Sandini, S., La Valle, R., Deaglio, S., Malavasi, F., Cassone, A., and De Bernardis, F. (2011). A highly immunogenic recombi-nant and truncated protein of the secreted aspartic proteases family (rSap2t) of Candida albicans as a mucosal anticandidal vaccine. FEMS Immunol. Med. Microbiol. 62, 215-224.
72. Schaller, M., Boeld, U., Oberbauer, S., Hamm, G., Hube, B., and Korting, H. C. (2004). Polymorphonu-clear leukocytes (PMNs) induce protective Th1-type cytokine epithelial responses in an in vitro model of oral candidosis. Microbiology 150, 2807-2813.
73. Shaykhiev, R., Behr, J., and Bals, R. (2008). Microbial patterns signaling via Toll-like receptors 2 and 5 contribute to epithelial repair, growth and survival. PLoS ONE 3, e1393. doi:10.1371/journal.pone. 0001393.
74. Sobel, J. D. (2007). Vulvovaginal candidosis. Lancet 369, 1961-1971.
75. Spellberg, B., Ibrahim, A. S., Yea-man, M. R., Lin, L., Fu, Y., Avane-sian, V., Bayer, A. S., Filler, S. G., Lipke, P., Otoo, H., and Edwards, J. E. Jr. (2008). The antifungal vaccine derived from the recombi-nant N terminus of Als3p protects mice against the bacterium Staphy-lococcus aureus. Infect. Immun. 76, 4574-4580.
76. Spellberg, B. J., Ibrahim, A. S., Avane-sian, V., Fu, Y., Myers, C., Phan, Q. T., Filler, S. G., Yeaman, M. R., and Edwards, J. E. Jr. (2006). Efficacy of the anti-Candida rAls3p-N or r Als 1p-N vaccines against disseminated and mucosal candidiasis. J. Infect. Dis. 194,256-260.
77. Stuehler, C., Khanna, N., Bozza, S., Zelante, T., Moretti, S., Kruhm, M., Lurati, S., Conrad, B., Worschech, E., Stevanovic, S., Krappmann, S., Einsele, H., Latge, J. P., Loef-fler, J., Romani, L., and Topp, M. S. (2011). Cross-protective TH1 immunity against Aspergillus fumi-gatus and Candida albicans. Blood 117,5881-5891.
78. Torosantucci, A., Bromuro, C., Chiani, P., De Bernardis, F., Berti, F., Galli, C., Norelli, F., Bellucci, C., Polonelli, L., Costantino, P., Rappuoli, R., and Cassone, A. (2005). A novel glyco-conjugate vaccine against fungal pathogens. J. Exp. Med. 202, 597-606.
79. Torosantucci, A., Chiani, P., Bromuro, C., De Bernardis, F., Palma, A. S., Liu, Y., Mignogna, G., Maras, B., Colone, M., Stringaro, A., Zam-boni, S., Feizi, T., and Cassone, A. (2009). Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence. PLoS ONE 4, e5392. doi:10.1371/journal.pone. 0005392
80. Trinchieri, G. (2003). Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3, 133-146.
81. Weindl, G., Naglik, J. R., Kaesler, S., Biedermann, T., Hube, B., Korting, H. C., and Schaller, M. (2007). Human epithelial cells establish direct antifungal defense through TLR4-mediated signaling. J. Clin. Invest. 117,3664-3672.
82. Wuthrich, M., Gern, B., Hung, C. Y., Ers-land, K., Rocco, N., Pick-Jacobs, J., Galles, K., Filutowicz, H., Warner, T., Evans, M., Cole, G., and Klein, B. (2011). Vaccine-induced protection against 3 systemic mycoses endemic to North America requires Th17 cells in mice. J. Clin. Invest. 121, 554-568.
83. Xin, H., Cartmell, J., Bailey, J. J., Dziadek, S., Bundle, D. R., and Cutler, J. E. (2012). Self-adjuvanting glycopeptide conjugate vaccine against disseminated candidiasis. PLoS ONE 7, e35106. doi:10.1371/journal.pone.0035106
84. Xin, H., and Cutler, J. E. (2011). Vaccine and monoclonal antibody that enhance mouse resistance to candidiasis. Clin. Vaccine Immunol. 18, 1656-1667.
85. Xin, H., Dziadek, S., Bundle, D. R., and Cutler, J. E. (2008). Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis. Proc. Natl. Acad. Sci. U.S.A. 105, 13526-13531.
86. Yang, Q., Wang, L., Lu, D. N., Gao, R. J., Song, J. N., Hua, P. Y., and Yuan, D. W. (2005). Prophylactic vaccination with phage-displayedepitope of C. albicans elicits protective immune responses against systemic candidiasis in C57BL/6 mice. Vaccine 23, 4088-4096.
87. Yano, J., Lilly, E., Barousse, M., and Fidel, P. L. Jr. (2010). Epithelial cell-derived S100 calcium-binding proteins as key mediators in the hallmark acute neutrophil response during Candida vaginitis. Infect. Immun. 78,5126-5137.
88. Zakikhany, K., Naglik, J. R., Schmidt-Westhausen, A., Holland, G., Schaller, M., and Hube, B. (2007). In vivo transcript profiling of Candida albicans identifies a gene essential for interepithelial dissemination. Cell. Microbiol. 9, 2938-2954.